Laboratorios Farmaceuticos Rovi, S.A. (0ILL.L)
EUR 62.2
(0.97%)
EUR 62.2
(0.97%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 263.09 Million EUR | 8.27% |
| 2022 | 243 Million EUR | 33.72% |
| 2021 | 181.72 Million EUR | 26.1% |
| 2020 | 144.1 Million EUR | -6.7% |
| 2019 | 154.45 Million EUR | 101.92% |
| 2018 | 76.49 Million EUR | -6.74% |
| 2017 | 82.02 Million EUR | 102.36% |
| 2016 | 40.53 Million EUR | -28.08% |
| 2015 | 56.36 Million EUR | -50.41% |
| 2014 | 113.66 Million EUR | 7.88% |
| 2013 | 105.36 Million EUR | 3.27% |
| 2012 | 102.02 Million EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 73.13 Million EUR | 10.22% |
| 2024 Q1 | 66.34 Million EUR | 1.57% |
| 2023 Q1 | 59.74 Million EUR | -17.39% |
| 2023 Q2 | 60.82 Million EUR | 1.81% |
| 2023 Q3 | 60.69 Million EUR | -0.22% |
| 2023 Q4 | 65.32 Million EUR | 7.63% |
| 2023 FY | 244.61 Million EUR | 0.66% |
| 2022 Q4 | 72.31 Million EUR | 22.3% |
| 2022 Q3 | 59.12 Million EUR | -2.17% |
| 2022 FY | 243 Million EUR | 33.72% |
| 2022 Q2 | 60.43 Million EUR | 19.0% |
| 2022 Q1 | 50.78 Million EUR | -8.81% |
| 2021 Q2 | 48.02 Million EUR | 53.12% |
| 2021 Q4 | 55.69 Million EUR | 19.43% |
| 2021 Q3 | 46.63 Million EUR | -2.89% |
| 2021 Q1 | 31.36 Million EUR | -28.63% |
| 2021 FY | 181.72 Million EUR | 26.1% |
| 2020 Q1 | 39.05 Million EUR | -17.92% |
| 2020 Q4 | 43.94 Million EUR | 5.86% |
| 2020 Q3 | 41.51 Million EUR | 6.49% |
| 2020 FY | 144.1 Million EUR | -6.7% |
| 2020 Q2 | 38.97 Million EUR | -0.2% |
| 2019 FY | 154.45 Million EUR | 101.92% |
| 2019 Q4 | 47.58 Million EUR | 25.86% |
| 2019 Q3 | 37.8 Million EUR | -15.26% |
| 2019 Q2 | 44.61 Million EUR | 14.52% |
| 2019 Q1 | 38.95 Million EUR | -5.37% |
| 2018 Q4 | 41.16 Million EUR | 15.6% |
| 2018 Q3 | 35.61 Million EUR | -12.33% |
| 2018 Q2 | 40.61 Million EUR | 11.93% |
| 2018 Q1 | 36.28 Million EUR | -9.97% |
| 2018 FY | 76.49 Million EUR | -6.74% |
| 2017 Q3 | 37.29 Million EUR | 17.22% |
| 2017 Q1 | 33.97 Million EUR | 2.37% |
| 2017 FY | 82.02 Million EUR | 102.36% |
| 2017 Q4 | 40.3 Million EUR | 8.07% |
| 2017 Q2 | 31.81 Million EUR | -6.36% |
| 2016 Q2 | 30.37 Million EUR | 18.11% |
| 2016 FY | 40.53 Million EUR | -28.08% |
| 2016 Q4 | 33.19 Million EUR | 3.23% |
| 2016 Q3 | 32.15 Million EUR | 5.85% |
| 2016 Q1 | 25.72 Million EUR | -22.31% |
| 2015 FY | 56.36 Million EUR | -50.41% |
| 2015 Q4 | 33.1 Million EUR | 3.62% |
| 2015 Q3 | 31.94 Million EUR | 4.44% |
| 2015 Q2 | 30.59 Million EUR | 8.26% |
| 2015 Q1 | 28.25 Million EUR | -13.25% |
| 2014 Q4 | 32.57 Million EUR | 17.56% |
| 2014 FY | 113.66 Million EUR | 7.88% |
| 2014 Q1 | 27.25 Million EUR | 2.59% |
| 2014 Q2 | 26.12 Million EUR | -4.15% |
| 2014 Q3 | 27.7 Million EUR | 6.05% |
| 2013 Q2 | 27.32 Million EUR | 11.05% |
| 2013 Q4 | 26.56 Million EUR | -1.09% |
| 2013 FY | 105.36 Million EUR | 3.27% |
| 2013 Q3 | 26.86 Million EUR | -1.7% |
| 2013 Q1 | 24.6 Million EUR | 2.94% |
| 2012 Q4 | 23.9 Million EUR | 0.0% |
| 2012 FY | 102.02 Million EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Boiron SA | 317.27 Million EUR | 17.078% |
| Vetoquinol SA | 217.11 Million EUR | -21.175% |
| Valneva SE | 134.92 Million EUR | -94.991% |
| AB Science S.A. | 14.01 Million EUR | -1777.069% |
| Nanobiotix S.A. | 62.98 Million EUR | -317.689% |
| PHAXIAM Therapeutics S.A. | 24.98 Million EUR | -952.95% |
| Vivoryon Therapeutics N.V. | 24.69 Million EUR | -965.487% |
| BioSenic S.A. | 7.58 Million EUR | -3369.471% |
| ABIVAX Société Anonyme | 127.37 Million EUR | -106.546% |
| Formycon AG | 23.73 Million EUR | -1008.541% |